The European Pharmaceutical Aerosol Group

EPAG AIM Workshop at
Workshop presentations are now available online - click here
 


"Bringining Value to the Patient in a Changing World"
March 29 - 31, 2011, Maryland, USA
Click here for more further information
 
The European Pharmaceutical Aerosol Group (EPAG) is a voluntary non-profit making consortium of member companies open to "European Pharmaceutical Companies that develop new products for human use utilising the Pulmonary or Nasal route of of delivery".  By sharing of non-confidential information, EPAG's objectives are:
  • To focus on Pharmaceutical issues relevant to Pulmonary and Nasal Delivery products, including clinical aspects as appropriate
     
  • Establish scientifically based best practices
     
  • Provide consensus comment to Industry and Government Agencies to promote safety and quality standards
     
  • To recommend harmonised standards and methodology

Members:
 3M, Almirall Sofotec, Aptar Pharma, AstraZeneca, Bespak Europe Ltd, Boehringer Ingelheim, Chiesi, Clinical Designs Ltd, GlaxoSmithKline, Hovione, Novartis, Pari, Pfizer, Philips Respironics, sanofi-aventis, SkyePharma, Teva, Trudell Medical International, Vectura, Zentiva Inhalations produkte GmbH

EPAG gratefully acknowledges the following companies that have hosted an EPAG meeting: Perlos/Medifiq (06/04), Wilden (06/05), Mikron Assemblies (09/05), Sagentia (03/08), Copley Scientific Ltd (11/08), and Medisize (04/09).